The Company considers all liquid investments with maturities of ninety days or less when purchased to be cash equivalents. As of April 30, 2013 and July 31, 2012, cash and cash equivalents were comprised of cash in checking accounts.
The Company’s activities to date have been supported by equity and debt financing. It has sustained losses in previous reporting periods with an inception to date loss of $11,578,300 as of April 30, 2013.
The Company does not currently believe its existing cash resources are sufficient to meet its anticipated needs during the next twelve months. The Company will require additional financing to fund its planned operations, including research and development, clinical trials and commercialization of the intellectual property acquired from Inovio pursuant to the Asset Purchase Agreement (as further described in Note 5). In addition, the Company will require additional financing in order to seek to license or acquire new assets, research and develop any potential patents and the related compounds, and obtain any further intellectual property that the Company may seek to acquire. Additional financing may not be available to the Company when needed or, if available, it may not be obtained on commercially reasonable terms. If the Company is not able to obtain the necessary additional financing on a timely basis, the Company will be forced to delay or scale down some or all of its development activities or perhaps even cease the operation of its business. Historically, the Company has funded its operations primarily through equity financings and it expects that it will continue to fund its operations through equity and debt financing. If the Company raises additional financing by issuing equity securities, its existing stockholders’ ownership will be diluted. Obtaining commercial loans, assuming those loans would be available, will increase the Company’s liabilities and future cash commitments. The Company also expects to pursue non-dilutive financing sources. However, obtaining such financing would require significant efforts by the Company’s management team, and such financing may not be available, and if available, could take a long period of time to obtain.
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. There is substantial doubt about the Company’s ability to continue as a going concern as the continuation of the Company’s business is dependent upon obtaining additional financing and the continued support of its stockholders to aid in financing operations. The consolidated financial statements do not include any adjustments that might result from this uncertainty
Think any of the data will be suitable for an SBIR Grant? Or an RFP from NIH? Or any of the cancer foundations? Those are all non-dilution sources and could be in preparation. I used to review SBIR Grants for NIH and they fund lots of novel concepts and potential clinical trials.
The only curious part is the startup of preclinical electroporation studies with an Old Dominion research group. But as I commented yesterday, Inovio is intramuscular electroporation to get a systemic response whereas ONCS is intra-lesion electroporation. Both take the same path to generate a systemic immune response, but one originates from the actual diseased tissue.
POINT?,,,,,,,er... your head ,,,,,,I don't have the patients for this stupidity............LAter!!! don't know why I bothered...........................sheesh........................have fun playin with yerself